Main

type

5 (blog/news article)

status

21 (imported old-v2, waiting for another import)

review version

0

cleanup version

0

pending deletion

0 (-)

created at

2025-12-30 19:00:49

updated at

2025-12-30 19:00:49

pol page id

3357645544

pol status

0

pol hosts ticketing

pol hosts ecommerce

pol hosts finance

pol hosts crypto

pol hosts leak

pol hosts devel

pol hosts ugc

linkedin.com

pol hosts klim

pol hosts builders

pol hosts self subdomains

pol hosts other subdomains

cdn.sanity.io

pol hosts other domains

pol updated

1768003804

Address

url

https://acsbrightedge.org/news/castle-biosciences-announces-pricing-of-initial-public-offering/

url length

95

url crc

41544

url crc32

316973640

location type

1 (url matches target location, page_location is empty)

canonical status

2 (missing canonical tag in html)

canonical page id

-

Source

domain id

80214181

domain tld

2688

domain parts

2

originating warc id

13194024

originating url

source type

11 (CommonCrawl)

Server response

server ip

3.33.186.135

Publication date

2025-08-02 22:12:48

Fetch attempts

0

Original html size

122990

Normalized and saved size

16389

Content

title

excerpt

content

Portfolio NewsCastle Biosciences Announces Pricing of Initial Public OfferingJuly 2024BrightEdge portfolio company, Castle Biosciences, has announced its intent to go publicFRIENDSWOOD, Texas—(BUSINESS WIRE) - Castle Biosciences, Inc. announced today the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $64.0 million. The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol "CSTL." All of the common stock in the offering is being offered by Castle Biosciences. The offering is expected to close on July 29, 2019, subject to customary closing conditions. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock.SVB Leerink and Bai...

author

updated

1768003804

Text analysis

block type

0

extracted fields

96

extracted bits

full content
content was extracted heuristically

detected location

0

detected language

1 (English)

category id

SEC and Crypto [en] (228)

index version

2025123101

paywall score

0

spam phrases

0

Text statistics

text nonlatin

0

text cyrillic

0

text characters

2189

text words

396

text unique words

222

text lines

1

text sentences

12

text paragraphs

1

text words per sentence

33

text matched phrases

1

text matched dictionaries

4